Skip to main content

Table 4 Comparison of relapse rates and disease backgrounds between patients with recurrent positive plasma EBV-DNA and other patients a

From: Clinical utility of plasma Epstein-Barr virus DNA monitoring in pediatric Epstein‐Barr virus-associated hemophagocytic lymphohistiocytosis: a Chinese retrospective observational study

 

Plasma EBV-DNA recurrently/persisitantly positive(n = 27)

Plasma EBV-DNA persistently negative(n = 23)

P

Relapse/refractory(n = 24)

23(85.2%)

1(4.3%)

<0.001

Sustained remission (n = 26)

4(14.8%)

22(95.7%)

 

Disease background

   

EBV-HLH(n = 41)

18(43.9%)

23(56.1%)

0.002

EBV-positive-lymphoma-HLH(n = 9)

9(100%)

0(0%)